AHA 2026: Novo reveals baseline data for Phase III ARTEMIS trial
Novo Nordisk’s IL-6 inhibitor ziltivekimab is being evaluated for reducing cardiovascular events following acute myocardial infarction.
Novo Nordisk’s IL-6 inhibitor ziltivekimab is being evaluated for reducing cardiovascular events following acute myocardial infarction.